Artivion closes Endospan acquisition after FDA approval for NEXUS aortic arch system

Artivion said it completed its acquisition of Endospan on May 18, 2026, closing a deal that followed FDA approval of Endospan’s NEXUS Aortic Arch System in April.

The company said the transaction was funded with a previously drawn $150 million delayed draw term loan. Artivion also said the deal includes additional contingent consideration tied to commercial performance.

The closing comes after a series of deal milestones in recent weeks. Artivion announced on April 7 that the U.S. Food and Drug Administration had approved NEXUS and said it could exercise its option to buy Endospan within 90 days. On May 7, the company said it had exercised that option and expected the acquisition to close in the second quarter.

Endospan separately confirmed the closing on May 18.

The FDA’s PMA record for the NEXUS Aortic Arch Stent Graft System lists a decision date of April 2 and a notice date of April 7. The approval cleared the way for Artivion to bring the vascular device developer fully into its portfolio.

The deal underscores how regulatory clearance can accelerate medtech M&A, especially for companies tied to a single flagship device.